Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Med Chem ; 64(15): 11418-11431, 2021 08 12.
Article in English | MEDLINE | ID: mdl-34279947

ABSTRACT

DAG-lactones represent useful templates for the design of potent and selective C1 domain ligands for PKC isozymes. The ester moiety at the sn-1 position, a common feature in this template, is relevant for C1 domain interactions, but it represents a labile group susceptible to endogenous esterases. An interesting challenge involves replacing the ester group of these ligands while still maintaining biological activity. Here, we present the synthesis and functional characterization of novel diacylglycerol-lactones containing heterocyclic ring substituents at the sn-1 position. Our results showed that the new compound 10B12, a DAG-lactone with an isoxazole ring, binds PKCα and PKCε with nanomolar affinity. Remarkably, 10B12 displays preferential selectivity for PKCε translocation in cells and induces a PKCε-dependent reorganization of the actin cytoskeleton into peripheral ruffles in lung cancer cells. We conclude that introducing a stable isoxazole ring as an ester surrogate in DAG-lactones emerges as a novel structural approach to achieve PKC isozyme selectivity.


Subject(s)
Diglycerides/pharmacology , Drug Design , Heterocyclic Compounds/pharmacology , Lactones/pharmacology , Protein Kinase C/metabolism , Diglycerides/chemical synthesis , Diglycerides/chemistry , Dose-Response Relationship, Drug , HeLa Cells , Heterocyclic Compounds/chemical synthesis , Heterocyclic Compounds/chemistry , Humans , Isoenzymes/metabolism , Lactones/chemical synthesis , Lactones/chemistry , Molecular Structure , Structure-Activity Relationship
2.
Bioorg Med Chem ; 25(12): 2971-2980, 2017 06 15.
Article in English | MEDLINE | ID: mdl-28392275

ABSTRACT

C1 domain-containing proteins, such as protein kinase C (PKC), have a central role in cellular signal transduction. Their involvement in many diseases, including cancer, cardiovascular disease, and immunological and neurological disorders has been extensively demonstrated and has prompted a search for small molecules to modulate their activity. By employing a diacylglycerol (DAG)-lactone template, we have been able to develop ultra potent analogs of diacylglycerol with nanomolar binding affinities approaching those of complex natural products such as phorbol esters and bryostatins. One current challenge is the development of selective ligands capable of discriminating between different protein family members. Recently, structure-activity relationship studies have shown that the introduction of an indole ring as a DAG-lactone substituent yielded selective Ras guanine nucleotide-releasing protein (RasGRP1) activators when compared to PKCα and PKCε. In the present work, we examine the effects of ligand selectivity relative to the orientation of the indole ring and the nature of the DAG-lactone template itself. Our results show that the indole ring must be attached to the lactone moiety through the sn-2 position in order to achieve RasGRP1 selectivity.


Subject(s)
DNA-Binding Proteins/metabolism , Guanine Nucleotide Exchange Factors/metabolism , Indoles/chemistry , Indoles/pharmacology , Lactones/chemistry , Lactones/pharmacology , Protein Kinase C-alpha/metabolism , Protein Kinase C-epsilon/metabolism , DNA-Binding Proteins/chemistry , Guanine Nucleotide Exchange Factors/chemistry , Humans , Molecular Docking Simulation , Protein Binding , Protein Domains , Protein Kinase C-alpha/chemistry , Protein Kinase C-epsilon/chemistry , Structure-Activity Relationship
3.
Bioorg Med Chem ; 22(12): 3123-40, 2014 Jun 15.
Article in English | MEDLINE | ID: mdl-24794745

ABSTRACT

The development of selective agents capable of discriminating between protein kinase C (PKC) isoforms and other diacylglycerol (DAG)-responsive C1 domain-containing proteins represents an important challenge. Recent studies have highlighted the role that Ras guanine nucleotide-releasing protein (RasGRP) isoforms play both in immune responses as well as in the development of prostate cancer and melanoma, suggesting that the discovery of selective ligands could have potential therapeutic value. Thus far, the N-methyl-substituted indololactone 1 is the agonist with the highest reported potency and selectivity for RasGRP relative to PKC. Here we present the synthesis, binding studies, cellular assays and biophysical analysis of interactions with model membranes of a family of regioisomers of 1 (compounds 2-5) that differ in the position of the linkage between the indole ring and the lactone moiety. These structural variations were studied to explore the interaction of the active complex (C1 domain-ligand) with cellular membranes, which is believed to be an important factor for selectivity in the activation of DAG-responsive C1 domain containing signaling proteins. All compounds were potent and selective activators of RasGRP when compared to PKCα with selectivities ranging from 6 to 65 fold. However, the parent compound 1 was appreciably more selective than any of the other isomers. In intact cells, modest differences in the patterns of translocation of the C1 domain targets were observed. Biophysical studies using giant vesicles as model membranes did show substantial differences in terms of molecular interactions impacting lipid organization, dynamics and membrane insertion. However, these differences did not yield correspondingly large changes in patterns of biological response, at least for the parameters examined.


Subject(s)
DNA-Binding Proteins/metabolism , Diglycerides/pharmacology , Guanine Nucleotide Exchange Factors/metabolism , Indoles/pharmacology , Lactones/pharmacology , Prostatic Neoplasms/pathology , Protein Kinase C/metabolism , Animals , CHO Cells , Cell Membrane/metabolism , Cells, Cultured , Cricetulus , Diglycerides/chemistry , Fluorescence Polarization , Fluorescence Resonance Energy Transfer , HEK293 Cells , Humans , Indoles/chemistry , Lactones/chemistry , Male , Models, Molecular , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Protein Isoforms
SELECTION OF CITATIONS
SEARCH DETAIL